{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:52:29Z","timestamp":1792507949020,"version":"4.5.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p>The UK National External Quality Assessment Service (NEQAS) provide an external proficiency testing (EPT) service for clinical laboratories. UK NEQAS for Histocompatibility and Immunogenetics (H&amp;amp;I) has been providing EPT schemes for over 45\u00a0years and has grown during this time to provide 19 EPT schemes. Accurate human leucocyte antigen (HLA) typing is critical to support safe clinical services, including transplantation, therefore high quality, relevant EPT schemes are required as part of a laboratory\u2019s quality assurance. This article reviews the development of the HLA typing EPT schemes, from the first HLA phenotyping scheme in 1975, via the first HLA genotyping scheme in 1992, through to the introduction in 2017 of HLA third field assessment results from next-generation sequencing technology. In addition, the introduction of EPT schemes to cover HLA associated diseases and pharmacogenetic reactions, including HLA-B27, HLA*B*57:01 and HLA-DQ for coeliac disease are discussed. The accuracy of laboratory EPT results for HLA phenotyping are &amp;gt;96% (2018\u20132022), HLA genotyping &amp;gt;99% (2020\u20132022), HLA-B27 testing &amp;gt;99% (2018\u20132022) and B*57:01 testing &amp;gt;99% (2017\u20132022). However, for HLA genotyping for coeliac disease 22%\u201346% of laboratories made errors in 2020\u20132022. On investigation, the high rate of unsatisfactory performance was attributed to laboratories lacking specific knowledge to interpret HLA genotyping results and accurately report HLA types for coeliac disease. A misleading commercial kit insert was also identified. The assessment of scheme results has uncovered several issues which have been addressed with the intention of educating participants and improving clinical services. The UK NEQAS for H&amp;amp;I EPT schemes have evolved over the past four decades to reflect changes in HLA typing technology, laboratory clinical practice and to cover post-analytical interpretative elements of HLA typing.<\/jats:p>","DOI":"10.3389\/fgene.2023.1272618","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T06:42:30Z","timestamp":1695105750000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["The history and evolution of HLA typing external proficiency testing schemes in UK NEQAS for H&amp;I"],"prefix":"10.3389","volume":"14","author":[{"given":"A.","family":"De\u2019Ath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. T.","family":"Rees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1399-0039.2006.00511.x","article-title":"Identification of a novel HLA-A allele (A*1115) in the UK national external quality assessment schemes for histocompatibility and Immunogenetics' educational cell exchange","volume":"67","author":"Bendukidze","year":"2006","journal-title":"Tissue Antigens"},{"key":"B2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/tan.12244","article-title":"A new HLA-A*03 null allele - A*03:162N caused by an exon 4 insertion and discovered during an external quality assessment exercise","volume":"83","author":"Bengtsson","year":"2014","journal-title":"Tissue Antigens"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1016\/j.transproceed.2010.07.020","article-title":"Human leukocyte antigen proficiency testing for central and eastern Europe: A summary of over 10 years of activity","volume":"42","author":"Bogunia-Kubik","year":"2010","journal-title":"Transpl. Proc."},{"key":"B4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1399-0039.1995.tb03127.x","article-title":"Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP)","volume":"46","author":"Bunce","year":"1995","journal-title":"Tissue Antigens"},{"key":"B5","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2217\/pgs.14.52","article-title":"Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: A meta-analytic review","volume":"15","author":"Cargnin","year":"2014","journal-title":"Pharmacogenomics"},{"key":"B6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/iji.12122","article-title":"External quality assessment of patient HLA-B*57:01 testing prior to abacavir prescription","volume":"41","author":"Darke","year":"2014","journal-title":"Int. J. Immunogenet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/iji.12434","article-title":"Results from the UK NEQAS for H&I scheme 8: HLA genotyping for coeliac and other HLA associated diseases","volume":"46","author":"De\u2019Ath","year":"2019","journal-title":"Int. J. Immunogenetics"},{"key":"B8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/j.1744-313X.2011.01040.x","article-title":"Human leucocyte antigen typing: techniques and technology, a critical appraisal","volume":"38","author":"Dunn","year":"2011","journal-title":"Int. J. Immunogenet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1399-0039.2012.01881.x","article-title":"HLA DNA typing: past, present, and future","volume":"80","author":"Erlich","year":"2012","journal-title":"Tissue Antigens"},{"key":"B10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1399-0039.2006.00639.x","article-title":"HLA-A*2312-a novel allele found during testing for the UK NEQAS for H&I DNA HLA-typing scheme","volume":"68","author":"Hammond","year":"2006","journal-title":"Tissue Antigens"},{"key":"B11","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1136\/jclinpath-2018-205209","article-title":"High rates of variation in HLA-DQ2\/DQ8 testing for coeliac disease: results from an RCPAQAP pilot program","volume":"71","author":"Horan","year":"2018","journal-title":"J. Clin. Pathol."},{"key":"B12","volume-title":"Conformity assessment: General requirements for proficiency testing. ISO:17043","year":"2010"},{"key":"B13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/iji.12464","article-title":"EFI region 8 balkan external proficiency testing for HLA typing: results of 15 years","volume":"47","author":"Kekik Cinar","year":"2020","journal-title":"Int. J. Immunogenet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1399-0039.1992.tb01940.x","article-title":"HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor\u2013recipient matching in cadaveric transplantation","volume":"39","author":"Olerup","year":"1992","journal-title":"Tissue Antigens"},{"key":"B15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/0167-5699(88)91190-5","article-title":"Histocompatibility typing \u2013 mac is back in town","volume":"9","author":"Parham","year":"1988","journal-title":"Trends Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3343\/alm.2017.37.5.365","article-title":"International organization for standardization (ISO)15189","volume":"37","author":"Schneider","year":"2017","journal-title":"Ann. Lab. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/j.1399-0039.2011.01700.x","article-title":"A new HLA-DQB1 sequence, DQB1*02:01:04, discovered during an external quality assessment exercise","volume":"78","author":"Smillie","year":"2011","journal-title":"Tissue Antigens"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/jamadermatol.2013.4114","article-title":"Relationship between the HLA-B*1502 allele and carbamazepine-induced stevens-johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis","volume":"149","author":"Tangamornsuksan","year":"2013","journal-title":"JAMA Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcv.2016.02.020","article-title":"First external quality assurance program of the Italian HLA-B*57:01 Network assessing the performance of clinical virology laboratories in HLA-B*57:01 testing","volume":"78","author":"Turriziani","year":"2016","journal-title":"J. Clin. Virol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/imj.12716","article-title":"Appropriate clinical use of human leukocyte antigen typing for coeliac disease: an australasian perspective","volume":"45","author":"Tye-Din","year":"2015","journal-title":"Intern Med. J."}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2023.1272618\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T06:42:36Z","timestamp":1695105756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2023.1272618\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,18]]},"references-count":20,"alternative-id":["10.3389\/fgene.2023.1272618"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2023.1272618","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,18]]},"article-number":"1272618"}}